Article
Oncology
Chaochao Wang, Hao Xue, Rongrong Zhao, Zhongzheng Sun, Xiao Gao, Yanhua Qi, Huizhi Wang, Jianye Xu, Lin Deng, Gang Li
Summary: It has been confirmed that RGS16 is upregulated in glioma tissues and its high expression is associated with poor survival. Deleting RGS16 significantly suppresses glioma cell proliferation and migration. Moreover, RGS16 has been validated as a direct target gene of miR let-7c-5p. Therefore, the inhibition of RGS16 may promote glioma progression and could potentially serve as a prognostic biomarker and therapeutic target for glioma.
FRONTIERS OF MEDICINE
(2023)
Article
Toxicology
Keke Luo, Yu Qin, Ting Ouyang, Xilan Wang, Aihua Zhang, Peng Luo, Xueli Pan
Summary: Endemic fluorosis is caused by high environmental fluoride intake and affects the teeth and bones. miRNAs play a crucial role in regulating bone metabolism and osteoblast proliferation and activation, with Let-7c-5p playing a key role in regulating CyclinD1 in fluoride-induced osteoblast proliferation and activation.
TOXICOLOGICAL SCIENCES
(2021)
Article
Cell Biology
Yat-Yin Law, Wei-Fang Lee, Chin-Jung Hsu, Yen-You Lin, Chun-Hao Tsai, Chien-Chung Huang, Min-Huan Wu, Chih-Hsin Tang, Ju-Fang Liu
Summary: The research on OA and RA revealed that miR-let-7c-5p and miR-149-5p have inhibitory effects on the transcription of proinflammatory cytokines, suggesting that increasing the expression of these two miRNAs is a novel therapeutic strategy for OA and RA.
Article
Genetics & Heredity
Wanjin Chen, Haibo Wang, Yuanlong Shen, Shouwen Wang, Deng Liu, Hongchuan Zhao, Guobin Wang, Fan Huang, Wei Wang, Ruolin Wu, Liujin Hou, Zhenghui Ye, Xinghua Zhang, Xiaoping Geng, Xiaojun Yu
Summary: The aim of this study was to investigate the effect of let-7c-5p on hepatocellular carcinoma (HCC) and its molecular pathway. The expression level of let-7c-5p was reduced in HCC and was associated with shorter survival time of HCC patients. Let-7c-5p inhibited HCC cell proliferation, invasion, and migration, and promoted apoptosis. CDCA8 was identified as a downstream mRNA of let-7c-5p that was negatively regulated by it. CDCA8 was found to be related to immune cells and immune pathways. Let-7c-5p suppresses HCC by down-regulating CDCA8, contributing to the understanding of HCC pathogenesis and drug development.
FUNCTIONAL & INTEGRATIVE GENOMICS
(2023)
Article
Endocrinology & Metabolism
Yun Liu, Chao-Yue Su, Yan-Yan Yan, Jian Wang, Jia-Jun Li, Ji-Jun Fu, Yu-Qing Wang, Jian-Ye Zhang
Summary: This research uncovers that exosomal let-7c-5p and miR-181b-5p derived from A549 cells can induce migration, invasion, and EMT in BEAS-2B cells, potentially through the regulation of focal adhesion and MAPK signaling pathway.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Liang Huang, Kai Lou, Kunyu Wang, Lingxin Liang, Yi Chen, Jichen Zhang
Summary: This study aimed to explore the impact of the let-7c-5p/CDC25A axis on cisplatin resistance in LUAD. The results showed that the downregulation of let-7c-5p and upregulation of CDC25A were associated with the development and cisplatin resistance of LUAD. Upregulation of let-7c-5p could inhibit LUAD cell proliferation, promote cell apoptosis, and arrest the cell cycle, enhancing the sensitivity of LUAD cells to cisplatin.
APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY
(2023)
Article
Cell Biology
Min Hou, Furong Luo, Yujie Ding, Xuan Bao, Xiaoyun Chen, Liangping Liu, Mingxing Wu
Summary: This study found that hsa-let-7c-3p is downregulated in fibrotic cataract, and overexpression of hsa-let-7c-3p can suppress LEC proliferation and migration, attenuate EMT, and inhibit ASC development. Hsa-let-7c-3p achieves these effects by directly targeting the CDH11 gene.
MOLECULAR AND CELLULAR BIOCHEMISTRY
(2023)
Article
Immunology
Xuechun Wang, Huijun Sun, Zhekai Hu, Peng Mei, Yanqi Wu, Min Zhu
Summary: The study found that NUTM2A-AS1 was up-regulated in LPS-stimulated human dental pulp cells (HDPCs), leading to cell damage. Silencing NUTM2A-AS1 attenuated LPS-induced injury through targeting the let-7c5p/HMGB1 axis.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Oncology
Xia-Lu Hong, Ta-Chung Yu, Xiao-Wen Huang, Ji-Lin Wang, Tian-Tian Sun, Ting-Ting Yan, Cheng-Bei Zhou, Hui-Min Chen, Wen-Yu Su, Wan Du, Hua Xiong
Summary: The study found that metformin can reverse colorectal cancer's resistance to chemotherapy induced by F. nucleatum, and it diminishes F. nucleatum-induced stemness by inhibiting sonic hedgehog signaling. Mechanistically, metformin targets the MYC/miR-361-5p cascade to reduce sonic hedgehog signaling proteins, thereby reversing F. nucleatum-induced stemness and rescuing F. nucleatum-triggered chemoresistance in CRC.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Bo You, Panpan Zhang, Miao Gu, Haimeng Yin, Yue Fan, Hui Yao, Si Pan, Haijing Xie, Tianyi Cheng, Huiting Liu, Yiwen You, Jisheng Liu
Summary: This study demonstrates that overexpression of let-7i-5p promotes the malignant phenotype in nasopharyngeal carcinoma (NPC) by inhibiting autophagy and targeting ATG10 and ATG16L1. Multiple clinically relevant indicators in NPC are associated with the expression of let-7i-5p.
Article
Biochemistry & Molecular Biology
Xiang Liu, Wei Zeng, Dayang Zheng, Min Tang, Wangyan Zhou
Summary: This study found that ESPL1 is upregulated in LUAD and promotes invasion, proliferation, and migration of LUAD cells. Furthermore, ESPL1 is a target gene of let-7c-5p. Let-7c-5p is downregulated in LUAD cells and plays a suppressive role, which is reversed by ESPL1. Therefore, let-7c-5p/ESPL1 may be potential therapeutic targets for LUAD.
MOLECULAR BIOTECHNOLOGY
(2022)
Article
Genetics & Heredity
Xiaodong Lv, Zhixian Fang, Weibo Qi, Yufen Xu, Wenyu Chen
Summary: This study investigates the relationship between the HOXA11-AS/let-7c-5p/IGF2BP1 regulatory axis and lung adenocarcinoma. HOXA11-AS promotes LUAD cell proliferation by targeting let-7c-5p/IGF2BP1, which could be potential molecular targets for LUAD.
FRONTIERS IN GENETICS
(2022)
Article
Microbiology
Ivone Jimenez-Toro, Carlos A. Rodriguez, Andres F. Zuluaga, Julian D. Otalvaro, Hector Perez-Madrid, Omar Vesga
Summary: Combination therapy with ampicillin plus ceftriaxone is the first-line treatment for severe infections caused by Enterococcus faecalis, but the pharmacokinetic/pharmacodynamic index linked to its efficacy has not been defined yet, hindering dose optimization in clinical settings.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2023)
Article
Biochemistry & Molecular Biology
Juanjuan Fu, Longmei Zhou, Sijin Li, Wenjing He, Jining Zheng, Zhiping Hou, Peiyuan He
Summary: This study found that let-7c-5p is highly expressed in colorectal cancer (CRC) and its overexpression promotes cell proliferation. Further investigation revealed that DUSP7 is the target gene of let-7c-5p and it exerts an anti-tumor effect by inhibiting the MAPK-ERK pathway. Additionally, let-7c-5p and DUSP7 have the potential to serve as prognostic biomarkers in CRC patients.
BIOCHEMICAL GENETICS
(2023)
Article
Biochemistry & Molecular Biology
Lisi Wang, Xiaolong Xiao, Hong Du
Summary: This study investigates the modulatory mechanism of let-7c-5p on the biological characteristics of lung adenocarcinoma (LUAD) cells by targeting AURKB. The findings suggest that let-7c-5p inhibits proliferation, migration, and invasion of LUAD cells, and promotes apoptosis, potentially providing new insights into the malignant progression of LUAD.
MOLECULAR BIOTECHNOLOGY
(2022)
Article
Pharmacology & Pharmacy
Hannah Petrek, Pui Yan Ho, Neelu Batra, Mei-Juan Tu, Qianyu Zhang, Jing-Xin Qiu, Ai-Ming Yu
Summary: This study introduces a novel technology for dual-targeting of two miRNAs in NSCLC cells, showing greater efficacy in inhibiting cell growth and colony formation compared to using individual miRNAs alone. Additionally, a specific miRNA-loaded nanomedicine demonstrated the best effectiveness in controlling tumor growth in NSCLC patient-derived xenograft mouse models.
BIOCHEMICAL PHARMACOLOGY
(2021)
Article
Pharmacology & Pharmacy
Young Hee Choi, Chao Zhang, Zhenzhen Liu, Mei-Juan Tu, Ai-Xi Yu, Ai-Ming Yu
Summary: This study developed a novel pharmacokinetic (PK)-pharmacodynamic (PD) model for assessing combination treatment by considering contributions from individual drugs, and incorporated the combination index method to define in vivo synergism accurately. The research found that sorafenib contributed more to tumor growth inhibition compared to coadministered doxorubicin, explaining previously inexplicable clinical observations. This model and strategy will have broad applications in translational research for identifying optimal dosage combinations with stronger synergy to improve therapeutic outcomes.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
(2021)
Editorial Material
Pharmacology & Pharmacy
Baitang Ning, Ai-Ming Yu
BIOCHEMICAL PHARMACOLOGY
(2021)
Article
Oncology
Xiong Zhang, Zenghong Huang, Junjian Wang, Zhao Ma, Joy Yang, Eva Corey, Christopher P. Evans, Ai-Ming Yu, Hong-Wu Chen
Summary: Prostate cancer is a common cancer in men with limited therapeutic options, but targeting drivers other than AR, such as RORgamma, may provide new treatment strategies. The study demonstrated that RORgamma antagonists effectively inhibit the growth of advanced prostate cancer tumors, suggesting a promising new approach for treating this aggressive disease.
Article
Pharmacology & Pharmacy
Joseph L. Jilek, Kayla L. Frost, Kevyn A. Jacobus, Wenxi He, Erica L. Toth, Michael Goedken, Nathan J. Cherrington
Summary: The study found that NASH-induced changes in transporter expression in the liver and kidneys may affect the metabolism and toxicity of CDDP in rats, leading to reduced nephrotoxicity and increased hepatic accumulation of CDDP. Alterations in renal and hepatic transporter expression in NASH rats may play a role in the clearance and sequestration of CDDP.
ACTA PHARMACEUTICA SINICA B
(2021)
Article
Pharmacology & Pharmacy
Siennah R. Miller, Joseph L. Jilek, Meghan E. McGrath, Raymond K. Hau, Erin Q. Jennings, James J. Galligan, Stephen H. Wright, Nathan J. Cherrington
Summary: ENTs play a crucial role in the testicular disposition of clofarabine, with pharmacological inhibition reducing drug uptake and potentially affecting the efficacy of ALL treatment.
PHARMACOLOGY RESEARCH & PERSPECTIVES
(2021)
Article
Pharmacology & Pharmacy
Joseph L. Jilek, Kayla L. Frost, Solene Marie, Cassandra M. Myers, Michael Goedken, Stephen H. Wright, Nathan J. Cherrington
Summary: This study reveals that nonalcoholic steatohepatitis (NASH) can affect the toxicokinetics and toxicity of ochratoxin A (OTA) in the kidney. Alterations in renal transporter expression caused by NASH can attenuate the excretion and uptake of OTA in the kidney, thereby reducing the nephrotoxicity of OTA.
DRUG METABOLISM AND DISPOSITION
(2022)
Article
Oncology
Anastasia L. Berg, Ashley Rowson-Hodel, Michelle Hu, Michael Keeling, Hao Wu, Kacey VanderVorst, Jenny J. Chen, Jason Hatakeyama, Joseph Jilek, Courtney A. Dreyer, Madelyn R. Wheeler, Ai-Ming Yu, Yuanpei Li, Kermit L. Carraway
Summary: Preventing drug resistance in cancer stem cells is crucial for improving treatment outcomes in cancer patients. This study found that cationic amphiphilic drugs can effectively target therapy-resistant cancer stem cell populations by inducing cell death through a different mechanism. This discovery has the potential to improve treatment outcomes for breast cancer patients and reduce the risk of tumor recurrence and metastasis.
Review
Pharmacology & Pharmacy
Gavin M. Traber, Ai-Ming Yu
Summary: RNA interference (RNAi) is a versatile method for regulating gene expression. Endogenous microRNAs (miRNAs) and exogenous small interfering RNAs (siRNAs) form RNA-induced silencing complexes to achieve gene regulation. RNAi-based drugs have been approved for clinical use and advancements in technology aim to improve their efficacy and safety. Chemical modifications and delivery platforms are being explored to enhance the structure, stability, and activity of RNA molecules. Novel biologic RNAi agents are also being developed for research purposes.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
(2023)
Article
Oncology
Shu Ning, Chengfei Liu, Wei Lou, Joy C. Yang, Alan P. Lombard, Leandro S. D'Abronzo, Neelu Batra, Ai-Ming Yu, Amy R. Leslie, Masuda Sharifi, Christopher P. Evans, Allen C. Gao
Summary: Next-generation antiandrogen drugs improve survival and quality of life in advanced prostate cancer patients, but resistance to these drugs is not well understood. This study found that the Wnt5a/FZD2 signaling pathway plays a critical role in promoting enzalutamide resistance, and targeting this pathway could be a potential therapy for advanced prostate cancer.
MOLECULAR CANCER THERAPEUTICS
(2022)
Article
Toxicology
Kayla L. Frost, Joseph L. Jilek, Austin D. Thompson, Robert R. Klein, Shripad Sinari, Elmira Torabzedehkorasani, Dean D. Billheimer, Rick G. Schnellmann, Nathan J. Cherrington
Summary: Inflammatory liver diseases have been found to cause renal pathology and dysfunction. Transcriptomic analysis and protein quantification revealed expression changes associated with immune regulation. This study provides insight into the mechanisms underlying the impact of liver dysfunction on renal physiology.
TOXICOLOGICAL SCIENCES
(2022)
Article
Pharmacology & Pharmacy
Kayla L. Frost, Joseph L. Jilek, Shripad Sinari, Robert R. Klein, Dean Billheimer, Stephen H. Wright, Nathan J. Cherrington
Summary: Alterations in hepatic transporters have been identified in precirrhotic chronic liver diseases, resulting in variations in drug metabolism and causing adverse drug reactions. However, the effect of chronic liver disease on renal transporters is unknown. This study found that the expression of certain organic anion transporters decreased in certain liver diseases, which could lead to drug accumulation and possible toxicity. Therefore, renal transporter changes should be considered in dose adjustments for patients with chronic liver disease.
DRUG METABOLISM AND DISPOSITION
(2023)
Article
Pharmacology & Pharmacy
Kayla L. Frost, Joseph L. Jilek, Erica L. Toth, Michael J. Goedken, Stephen H. Wright, Nathan J. Cherrington
Summary: Alterations in renal elimination processes can result in adverse drug reactions. This study investigates renal transporter changes in rodent models of NASH to identify a model that recapitulates human alterations.
DRUG METABOLISM AND DISPOSITION
(2023)
Review
Pharmacology & Pharmacy
Joseph M. Cronin, Ai -Ming Yu
Summary: The development of medications requires a thorough understanding of their pharmacokinetic and pharmacodynamic properties. The study of ADME gene products and their functions has been revolutionized by recombinant DNA technologies. These technologies enable the investigation of drug metabolism and disposition, as well as the study of posttranscriptional regulation of ADME genes.
DRUG METABOLISM AND DISPOSITION
(2023)
Article
Pharmacology & Pharmacy
Yixin Chen, Mei-Juan Tu, Fangwei Han, Zhenzhen Liu, Neelu Batra, Primo N. Lara, Hong -Wu Chen, Huichang Bi, Ai -Ming Yu
Summary: The research found that miR-22-3p, miR-9-5p, and miR-218-5p are antiproliferative miRNAs targeting non-small cell lung cancer (NSCLC) cells, and they inhibit folate metabolism and alter amino acid metabolism in NSCLC cells. In addition, the inhibition of glucose uptake by miR-22-3p and the reduction of serine biosynthesis from glucose by miR-9-5p and -218-5p were also confirmed. Recombinant miR-22-3p was more effective than miR-9-5p and -218-5p in inhibiting NSCLC cell respiration, glycolysis, and colony formation, without causing any toxicity.
ACTA PHARMACEUTICA SINICA B
(2023)